Tags Archive Navigation
icon
-
Media ReleaseNovartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis
-
Media ReleaseNovartis receives FDA Breakthrough Therapy designations for investigational STAMP inhibitor asciminib (ABL001) in chronic myeloid leukemia
-
Media ReleaseNovartis Entresto® granted expanded indication in chronic heart failure by FDA
-
Media ReleaseNovartis strengthens Oncology pipeline with successful closing of tislelizumab in-licensing
-
Media ReleaseDie Aktionäre von Novartis heissen an der Generalversammlung alle Anträge des Verwaltungsrats gut
-
Media ReleaseLes actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale annuelle
-
Media ReleaseNovartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
-
Media ReleaseNovartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer
-
Media ReleaseNew Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment
-
Media ReleaseNovartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)
-
Media ReleaseNovartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer
-
Media ReleaseWichtige Wachstumstreiber und Neueinführungen von Novartis setzen ihre Dynamik im ersten Quartal fort und erhalten das Vertrauen in das Wachstum; Konzernprognose für 2021 bestätigt
Pagination
- ‹ Previous page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- › Next page